Abrocitinib for Head and Neck Dermatitis: Case Series and Literature Review
JAK inhibitors, particularly abrocitinib and upadacitinib, may be considered as first-line therapies for refractory HND. They offer both rapid symptom relief and sustained efficacy.
Authors
- Jianxia Xiong (ORCID: https://orcid.org/0000-0002-4628-9263)
- T. Cai (ORCID: https://orcid.org/0000-0002-0533-8620)
- Yu Pan (ORCID: https://orcid.org/0000-0001-6468-4083)
- Chuan Liu (ORCID: https://orcid.org/0000-0003-0642-3154)
- Shuang Chen (ORCID: https://orcid.org/0000-0001-5254-6353)
- Aldi Dayu Saputra
Institutions
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Clinical Cosmetic and Investigational Dermatology
- Published
- 2025-11-01
- DOI
- https://doi.org/10.2147/ccid.s549045
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Centre Scientifique et Technique du Bâtiment